Metoprolol Retard Viatris

Metoprolol succinate, the active ingredient in Metoprolol Retard Viatris, is a beta‑adrenergic blocker presented as an extended‑release tablet for oral use. It is indicated for the management of hypertension, chronic stable angina, heart failure with reduced ejection fraction, and post‑myocardial infarction in adult patients.

GNH USA supplies Metoprolol Retard Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured for the EU market under strict regulatory standards, ensuring consistent potency and safety.

Metoprolol Retard is a selective β1‑adrenergic blocker used in cardiovascular disease management.

- Hypertension: lowers blood pressure by reducing heart rate, myocardial contractility and renin release. - Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain during exertion. - Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations by decreasing cardiac workload. - Post‑myocardial infarction: lowers risk of recurrent ischemic events and mortality.

Metoprolol Retard may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue - Dizziness or light‑headedness - Cold extremities - Gastrointestinal discomfort (nausea, abdominal pain)

Serious or Rare Side Effects: - Bradycardia or severe heart block - Acute heart failure exacerbation - Severe bronchospasm in patients with underlying airway disease

When prescribing Metoprolol Retard, clinicians should consider several precautionary measures to ensure safe use.

- Cardiovascular assessment: evaluate heart rate and blood pressure before initiation. - Concomitant β‑blocker therapy: avoid duplicate β‑blockade to prevent excessive bradycardia. - Asthma or chronic obstructive pulmonary disease: use with caution due to possible bronchoconstriction. - Diabetes mellitus: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms. - Surgery or anesthesia: discontinue or adjust dose prior to major procedures to avoid intra‑operative hypotension. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metoprolol Retard can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: combined use may cause profound bradycardia. - Calcium channel blockers (verapamil, diltiazem): increase risk of heart block and hypotension. - Antidiabetic agents (insulin, sulfonylureas): may enhance hypoglycaemia unawareness. - CYP2D6 inhibitors (paroxetine, fluoxetine): raise metoprolol plasma concentrations. - Clonidine abrupt withdrawal: may precipitate severe hypertension.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure for additive hypotensive effect. - NSAIDs: may reduce antihypertensive efficacy. - Antidepressants (tricyclics): observe for additive cardiac depression. - Antithyroid drugs: assess for altered heart rate response.